A First-in-human Study of KT502 in Adult Participants With Rheumatoid Arthritis (RA) | MicrobiomeTrials← Back to trialsNCT07564154
A First-in-human Study of KT502 in Adult Participants With Rheumatoid Arthritis (RA)
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-07-13Est. Completion: 2027-12
Enrollment target: 27 participants Locations- Kali Therapeutics Trial Site, Bayswater, Victoria, Australia
- Kali Therapeutics Trial Site, Auckland, NZ, New Zealand
Other microbiome trials you might be interested in
Rheumatoid ArthritisSystemic Lupus Erythematosus
This open-label, Phase I study will assess the safety and tolerability of surovatamig and characterise its PK and PD fol…
Birmingham, United StatesEst. completion Jun 27, 2028
Systemic SclerosisIdiopathic Inflammatory MyopathiesRheumatoid Arthritis
This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell th…
Tucson, United StatesEst. completion Feb 22, 2028